ICCC Stock Overview
An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ImmuCell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.69 |
| 52 Week High | US$5.64 |
| 52 Week Low | US$3.50 |
| Beta | 0.59 |
| 11 Month Change | -13.58% |
| 3 Month Change | -23.28% |
| 1 Year Change | -26.20% |
| 33 Year Change | -58.86% |
| 5 Year Change | -36.42% |
| Change since IPO | 269.00% |
Recent News & Updates
Recent updates
Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price
Aug 07
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price
May 27ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22ImmuCell reports FY20 preliminary sales
Jan 07ImmuCell restructures its bank debt
Dec 15ImmuCell EPS beats by $0.04, beats on revenue
Nov 12Shareholder Returns
| ICCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | 2.7% | 4.0% |
| 1Y | -26.2% | 15.4% | 24.9% |
Return vs Industry: ICCC underperformed the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: ICCC underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| ICCC volatility | |
|---|---|
| ICCC Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ICCC's share price has been volatile over the past 3 months.
Volatility Over Time: ICCC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 77 | Michael Brigham | immucell.com |
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
ImmuCell Corporation Fundamentals Summary
| ICCC fundamental statistics | |
|---|---|
| Market cap | US$28.12m |
| Earnings (TTM) | -US$4.05m |
| Revenue (TTM) | US$23.22m |
1.2x
P/S Ratio-7.1x
P/E RatioIs ICCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCC income statement (TTM) | |
|---|---|
| Revenue | US$23.22m |
| Cost of Revenue | US$16.95m |
| Gross Profit | US$6.27m |
| Other Expenses | US$10.32m |
| Earnings | -US$4.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 27.01% |
| Net Profit Margin | -17.44% |
| Debt/Equity Ratio | 48.0% |
How did ICCC perform over the long term?
See historical performance and comparison